Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.

Persons

Aaron Seth Kesselheim

Venue / Journal

Clin Pharmacol Ther

Date

Mon, 06/01/2009 - 12:00

Additional Journal Information

85(6):573-5

Authors

Kesselheim AS.

Pubmed URL

http://www.ncbi.nlm.nih.gov/pubmed/19451908